Breaking News Instant updates and real-time market news.

TRIL

Trillium Therapeutics

$2.48

-0.17 (-6.42%)

, AMC

AMC Entertainment

$7.12

0.26 (3.79%)

08:45
01/16/20
01/16
08:45
01/16/20
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Trillium Therapeutics (TRIL) 66.45% +1.76, AMC Entertainment (AMC) 46.71% +0.92, SmileDirectClub (SDC) 19.48% +0.52, Seabridge Gold (SA) 1.98% +0.24, Verastem (VSTM) 38.03% +0.19, Antero Midstream (AM) 27.95% +0.18, Direxion Daily Gold Miners Bull 3X Shares (NUGT) 1.39% +0.17, GDS Holdings (ADS) (GDS) 0.42% +0.13, iShares MSCI Europe (EUFN) 0.98% +0.10, and ArQule (ARQL) 0.81% +0.08.

TRIL

Trillium Therapeutics

$2.48

-0.17 (-6.42%)

AMC

AMC Entertainment

$7.12

0.26 (3.79%)

SDC

SmileDirectClub

$13.72

2 (17.06%)

SA

Seabridge Gold

$13.48

0.42 (3.22%)

VSTM

Verastem

$2.04

0.11 (5.70%)

AM

Antero Midstream

$7.59

0.18 (2.43%)

NUGT

Direxion Gold Miners Bull

$32.51

1.63 (5.28%)

GDS

GDS Holdings

$52.57

0.99 (1.92%)

ARQL

ArQule

$19.99

0.01 (0.05%)

  • 13

    Feb

  • 14

    Jan

TRIL Trillium Therapeutics
$2.48

-0.17 (-6.42%)

08/19/19
08/19/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Air Products (APD) downgraded to Neutral from Positive at Susquehanna. 2. Whiting Petroleum (WLL) downgraded to Sector Perform from Outperform at Scotiabank and to Equal Weight from Overweight at Stephens. 3. Celgene (CELG) and Amgen (AMGN) downgraded to Neutral from Buy at Mizuho. 4. Alliance Resource Partners (ARLP) and Peabody Energy (BTU) downgraded to Neutral from Overweight at JPMorgan. 5. Trillium Therapeutics (TRIL) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth saying the stock's 80% drop in price to 26c per share from $1.32 in the last six months could "lead to a cash crunch," leaving significant risk for its ability to raise sufficient capital to fund ongoing clinical studies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
HCWC
08/19/19
DOWNGRADE
HCWC
Neutral
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Trillium Therapeutics to Neutral from Buy, stating that the stock's 80% drop in price to 26c per share from $1.32 in the last six months could "lead to a cash crunch," leaving significant risk for its ability to raise sufficient capital to fund ongoing clinical studies. Additionally, the company has been unable to secure a replacement and remains without a CEO since Niclas Stiernholm resigned on April 30, noted Ramakanth.
03/12/19
HCWC
03/12/19
NO CHANGE
Target $4
HCWC
Buy
Trillium Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Trillium Therapeutics to $4 from $10 citing dilution from the recent capital raise and potential fund raises in the future. However, first look clinical results for TTI-622 in the second half of 2019 "could be a major catalyst for the stock," Ramakanth tells investors in a research note. He reiterates a Buy rating on the shares.
AMC AMC Entertainment
$7.12

0.26 (3.79%)

11/22/19
RILY
11/22/19
NO CHANGE
RILY
B. Riley FBR downgrades Cinemark and Marcus, cuts exhibitor targets
B. Riley FBR analyst Eric Wold revisited his exhibitor coverage heading into the "most important stretch" of the Q4 film slate, which will bring Frozen II, Jumanji: The Next Level, and Star Wars: The Rise of Skywalker to screens. However, with the quarter-to-date box office down 14.7%, the analyst now believes Q4 could be relatively flattish year-over-year versus consensus expectations for a mid-single-digit increase. As a result, he lowered his Q4 estimates for the group and believes the full-year 2019 box office could decline around 4.0%. Wold downgraded both Cinemark (CNK) and Marcus (MCS) to Neutral from Buy, saying short-term domestic box office movements are more likely to influence valuation decisions over the next 12-18 months. The analyst also lowered his price target for Buy-rated AMC Entertainment (AMC) to $15 from $19, for Buy-rated Imax (IMAX) to $30 from $34, and for Neutral-rated National CineMedia (NCMI) to $7.50 from $8.50.
12/18/19
BOFA
12/18/19
DOWNGRADE
BOFA
Underperform
AMC Entertainment downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Bryan Goldberg downgraded AMC Entertainment to Underperform from Neutral.
12/18/19
12/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Perform from Outperform at Oppenheimer with analyst Scott Schneeberger saying the company's Q2 results were weaker than expected on a lighter than expected Express/Ground segment performance. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation. 3. AMC Entertainment (AMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Bryan Goldberg saying he sees a "tough" compares for the 2020 film slate and highlights the lapping of Stubs A-List price increase. 4. Halliburton (HAL) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Boyd saying while down 7% year-to-date, Halliburton is the best performing large cap energy stock over the past three months on positive changes in frac fundamentals, macro improvements, and high short interest. 5. Galapagos (GLPG) downgraded to Neutral from Buy at Citi with analyst Nick Nieland saying he views the current valuation as fair and sees fewer clinical catalysts into the first half of 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/19
BOFA
12/18/19
DOWNGRADE
Target $7
BOFA
Underperform
BofA/Merrill downgrades AMC Entertainment to Underperform with $7 target
BofA/Merrill analyst Bryan Goldberg downgraded AMC Entertainment (AMC) to Underperform from Neutral with a price target of $7, down from $14. The analyst sees a "tough" compares for the 2020 film slate and highlights the lapping of Stubs A-List price increase. Further, he sees a continued rise in perceived competition from small screen competitors such as Netflix (NFLX) as well as high leverage at AMC.
SDC SmileDirectClub
$13.72

2 (17.06%)

01/14/20
STFL
01/14/20
NO CHANGE
Target $17
STFL
Buy
SmileDirectClub wholesale entrance offers 'incremental' sales, says Stifel
SmileDirectClub (SDC) this morning said it will start offering its clear aligners through the wholesale channel and sell to dentists and orthodontists rather than just directly to the consumer, Stifel analyst Jonathan Block tells investors in a research note. The company's wholesale initiative, if successful, would offer "largely incremental" revenue to its current direct-to-consumer model, contends the analyst. He keeps a Buy rating on SmileDirectClub with a $17 price target.
01/09/20
WOLF
01/09/20
INITIATION
Target $7
WOLF
Underperform
SmileDirectClub initiated with an Underperform at Wolfe Research
Wolfe Research initiated coverage of SmileDirectClub with an Underperform rating and $7 price target. While the firm believes multiple compression in 2019 has set up the stock up for outperformance on any positive surprise, its rating seeks to highlight the likelihood of deceleration, future capital raises, and the stock's macro and credit sensitivity.
01/06/20
CHLM
01/06/20
INITIATION
Target $20
CHLM
Buy
SmileDirectClub initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak initiated coverage of SmileDirectClub with a Buy rating and $20 price target. The company is is "upsetting the existing mold" of orthodontics by lowering physician involvement to provide increased access, better service and a reduced cost to the consumer, Nowak tells investors in a research note. The analyst believes SmileDirectClub is setting itself up for "many years of share gains while insulating itself from potential copy-cats." With 3% share today and a growing market, the company's business is "just getting going" and the current valuation is a good entry point for investors, contends Nowak. He expects its revenue to more than double in the next two years.
01/15/20
JEFF
01/15/20
NO CHANGE
JEFF
SmileDirect traditional channel entry makes competitive 'noise,' says Jefferies
Jefferies analyst Brandon Couillard said SmileDirectClub's (SDC) plans to enter the U.S. in-office, doctor-directed channel for aligners opens a new potential source of unit growth for the company and might soften scrutiny from the "dental establishment". Meanwhile, the move creates more competition "noise" for Align Technology (ALGN), Envista (NVST) and Dentsply Sirona (XRAY) and could be a source of near-term volatility for those stocks, although he said there is "still a lot to be fleshed out." While he thinks the negative read-throughs "are obvious," he said some potential positives include the fact that SmileDirect confirmed that the in-office market is still very relevant and that he sees clear differentiation between the aligners offered by Align and Envista when compared to SmileDirect.
SA Seabridge Gold
$13.48

0.42 (3.22%)

04/30/19
RILY
04/30/19
INITIATION
Target $22
RILY
Buy
Seabridge Gold initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Adam Graf started Seabridge Gold with a Buy rating and $22 price target. The company has been opportunistically buying gold properties over the last 20 years, improving the value, and monetizing the less promising assets, Graf tells investors in a research note. He believes Seabridge's flagship KSM asset is approaching monetization.
VSTM Verastem
$2.04

0.11 (5.70%)

06/20/19
JONE
06/20/19
NO CHANGE
JONE
Hold
JonesTrading downgrades Verastem as CEO marks third major management exit
As previously reported, JonesTrading analyst Matthew Cross downgraded Verastem to Hold from Buy after news that CEO Robert Forrester will be leaving the company. While this setback would have been "unexpected but manageable" by itself, the fact that this is the third major management departure gives him reason to pause and re-evaluate his view on the company, Cross tells investors. Despite Copiktra's initial difficulty, his talks with management leave him with reasons to be optimistic about a turnaround if the company can hit some of its goals in the next six months, added Cross.
05/14/19
ROTH
05/14/19
NO CHANGE
Target $4
ROTH
Buy
Verastem price target lowered to $4 from $14 at Roth Capital
Roth Capital analyst Jotin Marango lowered his price target for Verastem to $4 from $14 as the company's Q1 update leaves him uncertain about the strategy and extra time that Verastem may need to eventually unlock that commercial value. The analyst reiterates a Buy rating on the shares.
06/20/19
BTIG
06/20/19
DOWNGRADE
BTIG
Neutral
Verastem downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Verastem to Neutral from Buy.
06/20/19
JONE
06/20/19
DOWNGRADE
JONE
Hold
Verastem downgraded to Hold from Buy at JonesTrading
AM Antero Midstream
$7.59

0.18 (2.43%)

11/06/19
WELS
11/06/19
DOWNGRADE
WELS
Market Perform
Antero Midstream downgraded to Market Perform from Outperform at Wells Fargo
11/06/19
WELS
11/06/19
DOWNGRADE
Target $8
WELS
Market Perform
Antero Midstream downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Ned Baramov downgraded Antero Midstream (AM) to Market Perform from Outperform with a price target of $8, down from $10. The analyst cites the increased risk of a re-negotiation of midstream gathering rates, with its primary customer Antero Resources (AR) now looking at all contracts and operating expenses to improve its financial position. Baramov adds that Antero Resources remains under financial duress given low commodity prices and its high cost structure.
12/09/19
LTCO
12/09/19
NO CHANGE
LTCO
Antero Midstream price target lowered to $8 from $10 at Ladenburg
Ladenburg analyst Michael Schmitz reiterated a Buy rating on Antero Midstream, but lowered his price target to $8 from $10 after the company agreed to repurchase $100M of its shares from Antero Resources (AR), which Antero Midstream estimated "will result in $20M+ in total dividend savings in 2020." Additionally, Antero Midstream and Antero Resources agreed to a growth incentive fee program where "Antero Midstream will provide fee reductions to Antero Resources in 2020-2023, contingent upon Antero Resources achieving growth targets on low pressure gathering volumes."
10/03/19
JPMS
10/03/19
DOWNGRADE
Target $9
JPMS
Neutral
Antero Midstream reinstated with a Neutral rating at JPMorgan
Following a period of restriction, JPMorgan analyst Jeremy Tonet resumed coverage of Antero Midstream (AM) with a Neutral rating and a $9 price target, down from the Overweight rating and $22 price target the firm had on the stock prior to restriction. JPMorgan analyst Arun Jayaram resumed coverage of Antero Resources (AR) with an Underweight rating without a price target and Tonet said his own model feeds from the Antero Resources model, which forecasts 10% production CAGR through 2021 and flat production thereafter.
NUGT Direxion Gold Miners Bull
$32.51

1.63 (5.28%)

GDS GDS Holdings
$52.57

0.99 (1.92%)

11/18/19
RBCM
11/18/19
NO CHANGE
Target $62
RBCM
Outperform
GDS Holdings price target raised to $62 from $58 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on GDS Holdings to $62 and kept his Outperform rating after its Q3 results, saying the financials for the quarter were "solid" as the company develops its resource pipeline in and near the "Tier 1 markets." The analyst further cites the management's raised guidance for FY19 EBITDA while noting that his expectations for 2020 sales pipeline look "promising".
01/14/20
01/14/20
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CyberArk (CYBR) initiated with a Neutral at DA Davidson. 2. ConocoPhillips (COP) initiated with a Positive at Susquehanna. 3. DuPont (DD) initiated with a Buy at Gordon Haskett. 4. Valero (VLO) initiated with an Overweight at Barclays. 5. GDS Holdings (GDS) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/14/20
MACQ
01/14/20
INITIATION
Target $60
MACQ
Outperform
GDS Holdings initiated with an Outperform at Macquarie
Macquarie initiated coverage of GDS Holdings with an Outperform rating and $60 price target.
12/13/19
RHCO
12/13/19
NO CHANGE
Target $55
RHCO
Buy
GDS Holdings price target raised to $55 from $51 at SunTrust
SunTrust analyst Greg Miller raised his price target on GDS Holdings to $55 and kept his Buy rating after meeting with its management. The analyst says the discussion affirmed the company's market opportunity in China, where data center demand relative to existing supply remains "extremely strong", and he expects the existing growth rate in the market to carry over into 2021.
ARQL ArQule
$19.99

0.01 (0.05%)

12/10/19
RBCM
12/10/19
DOWNGRADE
Target $20
RBCM
Sector Perform
ArQule downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Gregory Renza downgraded ArQule (ARQL) to Sector Perform from Outperform with a $20 price target to reflect the company's agreement to be acquired by Merck (MRK).
12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.

TODAY'S FREE FLY STORIES

06:40
01/20/20
01/20
06:40
01/20/20
06:40
General news
FX Action: USD-JPY has gone into narrow-range mode »

FX Action: USD-JPY has…

AMRC

Ameresco

$19.78

-0.1 (-0.50%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
Ameresco management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

HRB

H&R Block

$24.48

-0.48 (-1.92%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
H&R Block management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

MSM

MSC Industrial

$76.89

-1.58 (-2.01%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
MSC Industrial management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 29

    Jan

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.